FDA approves Romvimza for tenosynovial giant cell tumor (TGCT)
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...
Medindia3d
FDA Approves Vimseltinib to Treat Tenosynovial Giant Cell Tumor
Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, ...
BioSpace6d
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...
Monthly Prescribing Reference5d
Romvimza Approved for Symptomatic Tenosynovial Giant Cell Tumor
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
News Medical4d
Vimseltinib gains FDA approval for treating tenosynovial giant cell tumor
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the ...
MedPage Today10d
Second Drug for Benign Synovial Tumor Condition Wins FDA Approval
Opens in a new tab or window The FDA approved the small-molecule inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumor (TGCT), a rare, non-malignant ...
Morningstar9d
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) In the MOTION Phase 3 study, ROMVIMZA met primary ...
Medical Xpress4d
FDA approves Romvimza for tenosynovial giant cell tumor (TGCT)
Get Instant Summarized Text (Gist) The FDA has approved vimseltinib (Romvimza) for treating tenosynovial giant cell tumor (TGCT), a non-cancerous joint tissue tumor. In a Phase III trial, 67% of ...
Targeted Oncology9d
Vimseltinib Gains FDA Approval in Tenosynovial Giant Cell Tumor
Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the ...
Medscape9d
FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumors
The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult ...
EurekAlert!5d
FDA approves vimseltinib for tenosynovial giant cell tumor (TGCT)
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the ...